Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Pitavastatin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR known ✓ | P04035 | 5/20 | 0.85 |
| ▸ | PDE4D | Q08499 | 3/20 | 1.00 |
| ▸ | NR4A2 | P43354 | 2/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 2/20 | 1.00 |
| ▸ | RXRA | P19793 | 3/20 | 0.85 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.54 |
| ▸ | SIRT6 | Q8N6T7 | 2/20 | 0.54 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.54 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.54 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.54 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.54 |
| ▸ | PGR | P06401 | 1/20 | 0.54 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.54 |
| ▸ | CCKAR | P32238 | 1/20 | 0.54 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.54 |
| ▸ | SLC10A1 | Q14973 | 1/20 | 0.54 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.53 |
| ▸ | ESR1 | P03372 | 1/20 | 0.51 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.51 |
| ▸ | PDE4A | P27815 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pitavastatin SCHEMBL1582325 | 1.00 | PDE4D (1.00) | PDE4DNR4A2NR1I2HMGCRRXRA | |
| Pitavastatin SCHEMBL6068297 | 1.00 | PDE4D (1.00) | PDE4DNR4A2NR1I2HMGCRRXRA | |
| Pitavastatin SCHEMBL2878734 | 1.00 | PDE4D (1.00) | PDE4DNR4A2NR1I2HMGCRRXRA | |
| Pitavastatin SCHEMBL13278896 | 1.00 | PDE4D (1.00) | PDE4DNR4A2NR1I2HMGCRRXRA | |
| Pitavastatin SCHEMBL6068293 | 1.00 | PDE4D (1.00) | PDE4DNR4A2NR1I2HMGCRRXRA | |
| Pitavastatin SCHEMBL1582328 | 1.00 | PDE4D (1.00) | PDE4DNR4A2NR1I2HMGCRRXRA | |
| Pitavastatin SCHEMBL13278902 | 1.00 | PDE4D (1.00) | PDE4DNR4A2NR1I2HMGCRRXRA | |
| Pitavastatin SCHEMBL13278898 | 1.00 | PDE4D (1.00) | PDE4DNR4A2NR1I2HMGCRRXRA | |
| Pitavastatin SCHEMBL2878736 | 1.00 | PDE4D (1.00) | PDE4DNR4A2NR1I2HMGCRRXRA | |
| Pitavastatin SCHEMBL3369 | 1.00 | PDE4D (1.00) | PDE4DNR4A2NR1I2HMGCRRXRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1539698-B1 | METHOD FOR PRODUCING A 3,5-DIHYDROXY-6-HEPTENOATE | NISSAN CHEMICAL IND LTD (JP) | 2010-10-20 | — | — | EP | disclosed |
| US-7550596-B2 | Method of producing ethyl (3R, 5S, 6E)-7-[2 cyclopropyl-4-(fluorophenyl) quinoline-3-yl]-3, 5-dihydroxy-6-heptenoate | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2009-06-23 | — | — | US | disclosed |
| US-7339062-B2 | Method for producing a 3,5-dihydroxy-6-heptenoate | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2008-03-04 | — | — | US | disclosed |
| US-20060167260-A1 | Method for producing a 3,5-dihydroxy-6-heptenoate | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2006-07-27 | — | — | US | disclosed |
| US-20060089381-A1 | Method of producing Ethyl (3R, 5S, 6E)-7-[2 cyclopropyl-4-(fluorophenyl) quinoline-3-yl]-3, 5-dihydroxy-6-heptenoate | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2006-04-27 | — | — | US | disclosed |
| US-5369109-A | Optically active esters of 7-substituted 3,5-difunctionalized 6-heptenoic acids | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 1994-11-29 | — | — | US | disclosed |
| EP-0475627-B1 | Optically active esters of 7-substituted 3,5-difunctionalized 6-heptenoic acids | SAGAMI CHEM RES (JP) | 1994-10-19 | — | — | EP | disclosed |
| US-5276154-A | Optically active esters of 7-substituted 3,5-difunctionalized 6-heptenoic acids | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 1994-01-04 | — | — | US | disclosed |
| EP-0475627-A1 | Optically active esters of 7-substituted 3,5-difunctionalized 6-heptenoic acids | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 1992-03-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060089381-A1 | Method of producing Ethyl (3R, 5S, 6E)-7-[2 cyclopropyl-4-(fluorophenyl) quinoline-3-yl]-3, 5-dihydroxy-6-heptenoate | UGT1A6, RPL6, CXCR6 | HMGCR 634/4885PDE4D 666/4885NR4A2 3641/4885 |
| US-20060167260-A1 | Method for producing a 3,5-dihydroxy-6-heptenoate | HMGCR, DHCR7, CYP46A1 | HMGCR 1/4885PDE4D 1756/4885NR4A2 1603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.